Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($1.64), $0.47 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $4.84 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.